Pay-For-Delay Antitrust Test Sets Bar Too High: FTC Official
By Melissa Lipman ( January 24, 2013, 8:10 PM EST) -- A top Federal Trade Commission antitrust official warned Thursday that an antitrust standard holding pay-for-delay pharmaceutical patent settlements generally legal overvalues weaker patents without offering any benefits for consumers....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.